Looks like you’re on the US site. Choose another location to see content specific to your location
Getinge AB: A Leading Medtech Innovator Expanding in North America

Albert Baines
Getinge AB, a prominent Swedish company in medical technology, is poised for significant growth in North America, offering innovative solutions for operating rooms, ICUs, and sterile reprocessing. With a strong international presence, Getinge capitalizes on the increasing healthcare needs driven by demographic changes, providing a robust platform for regional and global investors.
Headquartered in Gothenburg, Sweden, Getinge AB operates as a global leader in acute care solutions. The company’s portfolio spans Acute Care Therapies, Applied Patient Handling, and Life Sciences sectors, addressing essential needs in surgery, patient support, and pharmaceutical bioprocessing. Through a mix of high-margin equipment and recurring revenues from services and consumables, Getinge ensures operational stability and reduces reliance on single markets or products. Their strategic focus on North America leverages the region’s commitment to advanced medical technologies, offering investors a reliable exposure to this essential sector. Known for innovative products like Servo ventilators and Maquet surgical tables, Getinge maintains a competitive edge against giants like Medtronic and Stryker. The company’s commitment to integrated solutions resonates well with hospitals seeking efficiency improvements, solidifying its market leadership across continents.
As global demand for healthcare infrastructure grows, Getinge AB remains at the forefront of delivering cutting-edge medical solutions. With significant opportunities in North America, the company maintains a promising trajectory, supported by demographic shifts and increased healthcare investments. This positions Getinge as an attractive choice for investors seeking stability and growth in the medtech industry.
Stay informed
Receive the latest industry news, Tips and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard